Verrica Pharmaceuticals (NASDAQ:VRCA) Now Covered by Analysts at Lake Street Capital

Research analysts at Lake Street Capital assumed coverage on shares of Verrica Pharmaceuticals (NASDAQ:VRCA) in a research note issued on Thursday. The brokerage set a “buy” rating and a $9.00 price target on the stock. Lake Street Capital’s price objective points to a potential upside of 83.30% from the stock’s current price.

A number of other analysts also recently issued reports on the company. HC Wainwright assumed coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $12.67.

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $4.91 on Thursday. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The stock has a market cap of $84.35 million, a price-to-earnings ratio of -2.94 and a beta of 1.49. The business has a fifty day moving average of $5.54 and a two-hundred day moving average of $5.82.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VRCA. Renaissance Technologies LLC lifted its position in shares of Verrica Pharmaceuticals by 22.6% during the first quarter. Renaissance Technologies LLC now owns 32,360 shares of the company’s stock worth $171,000 after purchasing an additional 5,960 shares in the last quarter. XTX Topco Ltd purchased a new stake in Verrica Pharmaceuticals during the 4th quarter worth approximately $122,000. Quadrature Capital Ltd acquired a new stake in Verrica Pharmaceuticals during the 4th quarter worth approximately $99,000. Man Group plc purchased a new position in Verrica Pharmaceuticals in the 4th quarter valued at approximately $94,000. Finally, Armistice Capital LLC grew its stake in shares of Verrica Pharmaceuticals by 75.1% in the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after acquiring an additional 479,732 shares in the last quarter. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.